PEOPLE - Ceapro makes appointment:
This article was originally published in Clinica
Edmonton, Alberta-based Ceapro has appointed Oleh Hnatiuk as acting managing director of its Ceapro Technology subsidiary. He will have supervision of the commercial activities relating to AccuScreen, the group's type 2 diabetes early detection test. Mr Hnatiuk is president of technology commercialisation advisory company Connect Capital Corp and was formerly president of University Technologies International. His skills and experience in networking will be employed at a critical time for the commercial introduction of AccuScreen, said Ceapro president and CEO Dr Mark Redmond.
You may also be interested in...
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Following Aspen’s admission last year that it was party to an illegal, anti-competitive agreement on fludrocortisone, Tiofarma has now also conceded to the UK’s Competition and Markets Authority that it took part in the deal.